Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Spermosens AB (publ) ("Spermosens" or the "Company") is pleased to announce the appointment of Dr. Jaime Castillo-León as Chief Technology Officer (CTO) as part of the plan to advance JUNO-Checked technology and establish licensing agreements with leading players in the assisted reproductive technology (ART) market. Strengthening the team's technology expertise is a key step in executing the Company's recently announced plan to achieve positive cash flow from the second half of 2026.
Dr. Castillo-León, an expert in biosensors, microfluidics and lab-on-a-chip technologies, has joined Spermosens as CTO from April 1st. With over two decades of experience in biomedical engineering and diagnostic systems, Dr. Castillo-León brings the expertise needed to further develop JUNO-Checked, ensuring commercial viability and scalability. He holds a Ph.D. in electrochemical biosensors for biomedical applications from Lund University and has previously served as a Senior Researcher at DTU, where he contributed to multiple high-impact projects in the field of biomedical diagnostics.
As CTO, Dr. Castillo-León will lead Spermosens' technology maturation efforts, focusing on optimizing JUNO-Checked to improve accuracy, efficiency and integration with commercially available instruments. This work, in collaboration with partners such as FlexMedical Solutions and PalmSens, is a critical part of the Company's strategy to secure licensing agreements with upfront payments, milestones and royalties on net sales.
Tore Duvold, CEO of Spermosens, comments: "With our plan in place and a clear path towards commercialization, strengthening our team is an important next step. Jaime's expertise in biosensors and microfluidics will be instrumental as we refine our technology and work towards securing partnerships. His addition to the team reinforces our commitment to executing our plan and unlocking the commercial potential of JUNO-Checked."
Jaime Castillo-León, CTO of Spermosens, comments: "I am excited to join Spermosens at this crucial stage, where technological refinement and commercial strategy come together. The Company's innovative approach to fertility diagnostics presents a unique opportunity to make a meaningful impact in reproductive healthcare. I look forward to contributing to the development and commercialization of JUNO-Checked, helping to bring this breakthrough technology to market."
The appointment of Dr. Castillo-León follows the recent strategic investment of SEK 10.8 million, which strengthened the Company's financial foundation to accelerate product development and business development efforts. With a reinforced leadership team, Spermosens remains focused on executing its plan to achieve positive cash flow and deliver innovative solutions to the ART market.
For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com
Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com